Which has stronger valuation & earnings, PRTA or ALVO?

Alvotech has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 45.86 -$244.09M -$0.84 N/A Alvotech $588.90M 3.00 $27.92M -$0.61 N/A

Is PRTA or ALVO more profitable?

Alvotech has a net margin of -36.31% compared to Prothena's net margin of -80.68%. Alvotech's return on equity of 0.00% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Alvotech -36.31% N/A -11.73%

Does the media refer more to PRTA or ALVO?

In the previous week, Alvotech had 14 more articles in the media than Prothena. MarketBeat recorded 18 mentions for Alvotech and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Alvotech's score of 0.78 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 6 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or PRTA?

In the previous week, Vir Biotechnology had 5 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Vir Biotechnology's score of 0.12 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NVAX or PRTA?

Novavax has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.65 $440.30M -$1.52 N/A Prothena $9.68M 45.86 -$244.09M -$0.84 N/A

Is NVAX or PRTA more profitable?

Novavax has a net margin of -59.87% compared to Prothena's net margin of -80.68%. Novavax's return on equity of -14.82% beat Prothena's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Prothena -80.68% -16.45% -14.51%

Does the media prefer NVAX or PRTA?

In the previous week, Novavax had 22 more articles in the media than Prothena. MarketBeat recorded 26 mentions for Novavax and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Novavax's score of 0.00 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 7 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 4 Very Negative mention(s) Neutral Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZBIO or PRTA more profitable?

Zenas BioPharma has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -122.45% -58.04% Prothena -80.68% -16.45% -14.51%

Does the media prefer ZBIO or PRTA?

In the previous week, Zenas BioPharma had 6 more articles in the media than Prothena. MarketBeat recorded 10 mentions for Zenas BioPharma and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Zenas BioPharma's score of 0.32 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 0 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, PRTA or ABSI?

Absci has lower revenue, but higher earnings than Prothena. Absci is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $9.68M 45.86 -$244.09M -$0.84 N/A Absci $2.80M 565.09 -$115.18M -$0.80 N/A

Is PRTA or ABSI more profitable?

Prothena has a net margin of -80.68% compared to Absci's net margin of -7,756.38%. Prothena's return on equity of -16.45% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Prothena -80.68% -16.45% -14.51% Absci -7,756.38% -61.71% -54.52%

Does the media prefer PRTA or ABSI?

In the previous week, Absci had 1 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Absci and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Absci's score of 0.40 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Absci 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prothena (PRTA) Competitors

$8.63 +0.15 (+1.82%)

Closing price 03:59 PM Eastern

Extended Trading

$8.62 -0.01 (-0.16%)

As of 04:04 PM Eastern

Compare

PRTA vs. ALVO, VIR, NVAX, ZBIO, and ABSI

Should you buy Prothena stock or one of its competitors? Prothena's main competitors and comparable companies include Alvotech (ALVO), Vir Biotechnology (VIR), Novavax (NVAX), Zenas BioPharma (ZBIO), and Absci (ABSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prothena compare to Alvotech?

Prothena (NASDAQ:PRTA) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Prothena currently has a consensus target price of $24.57, indicating a potential upside of 189.76%. Alvotech has a consensus target price of $8.50, indicating a potential upside of 45.30%. Given Prothena's stronger consensus rating and higher probable upside, research analysts clearly believe Prothena is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Prothena has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

97.1% of Prothena shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alvotech has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.86	-$244.09M	-$0.84	N/A
Alvotech	$588.90M	3.00	$27.92M	-$0.61	N/A

Alvotech has a net margin of -36.31% compared to Prothena's net margin of -80.68%. Alvotech's return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Alvotech	-36.31%	N/A	-11.73%

In the previous week, Alvotech had 14 more articles in the media than Prothena. MarketBeat recorded 18 mentions for Alvotech and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Alvotech's score of 0.78 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	6 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alvotech beats Prothena on 9 of the 16 factors compared between the two stocks.

How does Prothena compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Vir Biotechnology has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Prothena	-80.68%	-16.45%	-14.51%

In the previous week, Vir Biotechnology had 5 more articles in the media than Prothena. MarketBeat recorded 9 mentions for Vir Biotechnology and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Vir Biotechnology's score of 0.12 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vir Biotechnology presently has a consensus target price of $21.86, indicating a potential upside of 89.73%. Prothena has a consensus target price of $24.57, indicating a potential upside of 189.76%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Vir Biotechnology has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Prothena has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market.

Prothena has lower revenue, but higher earnings than Vir Biotechnology. Prothena is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	28.43	-$437.99M	-$1.86	N/A
Prothena	$9.68M	45.86	-$244.09M	-$0.84	N/A

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Prothena beats Vir Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Prothena compare to Novavax?

Novavax (NASDAQ:NVAX) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Novavax has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.65	$440.30M	-$1.52	N/A
Prothena	$9.68M	45.86	-$244.09M	-$0.84	N/A

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 24.78%. Prothena has a consensus price target of $24.57, indicating a potential upside of 189.76%. Given Prothena's stronger consensus rating and higher probable upside, analysts plainly believe Prothena is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

53.0% of Novavax shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Novavax has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Prothena has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market.

In the previous week, Novavax had 22 more articles in the media than Prothena. MarketBeat recorded 26 mentions for Novavax and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Novavax's score of 0.00 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	7 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	4 Very Negative mention(s)	Neutral
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a net margin of -59.87% compared to Prothena's net margin of -80.68%. Novavax's return on equity of -14.82% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Prothena	-80.68%	-16.45%	-14.51%

Summary

Novavax and Prothena tied by winning 8 of the 16 factors compared between the two stocks.

How does Prothena compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Zenas BioPharma has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Prothena has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market.

Zenas BioPharma has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Prothena	-80.68%	-16.45%	-14.51%

Zenas BioPharma currently has a consensus price target of $46.71, indicating a potential upside of 65.77%. Prothena has a consensus price target of $24.57, indicating a potential upside of 189.76%. Given Prothena's stronger consensus rating and higher probable upside, analysts clearly believe Prothena is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Prothena has lower revenue, but higher earnings than Zenas BioPharma. Prothena is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	183.68	-$377.74M	-$8.99	N/A
Prothena	$9.68M	45.86	-$244.09M	-$0.84	N/A

97.1% of Prothena shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Zenas BioPharma had 6 more articles in the media than Prothena. MarketBeat recorded 10 mentions for Zenas BioPharma and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Zenas BioPharma's score of 0.32 indicating that Prothena is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	0 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prothena beats Zenas BioPharma on 10 of the 17 factors compared between the two stocks.

How does Prothena compare to Absci?

Prothena (NASDAQ:PRTA) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

In the previous week, Absci had 1 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Absci and 4 mentions for Prothena. Prothena's average media sentiment score of 1.35 beat Absci's score of 0.40 indicating that Prothena is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Absci	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Absci has lower revenue, but higher earnings than Prothena. Absci is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	45.86	-$244.09M	-$0.84	N/A
Absci	$2.80M	565.09	-$115.18M	-$0.80	N/A

Prothena currently has a consensus target price of $24.57, indicating a potential upside of 189.76%. Absci has a consensus target price of $13.71, indicating a potential upside of 48.74%. Given Prothena's higher possible upside, research analysts plainly believe Prothena is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Prothena has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Absci has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market.

Prothena has a net margin of -80.68% compared to Absci's net margin of -7,756.38%. Prothena's return on equity of -16.45% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Absci	-7,756.38%	-61.71%	-54.52%

97.1% of Prothena shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 10.4% of Prothena shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Prothena beats Absci on 9 of the 17 factors compared between the two stocks.

Get Prothena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTA vs. The Competition

Export

Metric	Prothena	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$451.99M	$3.82B	$7.13B	$13.20B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-10.28	14.02	275.17	25.93
Price / Sales	46.69	1,174.57	566.33	83.66
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	1.66	16.10	10.80	6.27
Net Income	-$244.09M	-$22.69M	$3.50B	$382.13M
7 Day Performance	1.10%	-3.42%	-1.96%	-1.34%
1 Month Performance	-9.50%	-12.63%	-7.50%	-5.58%
1 Year Performance	-16.58%	9.66%	3.41%	-1.52%

Prothena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTA Prothena	3.276 of 5 stars	$8.63 +1.8%	$24.57 +184.6%	-16.6%	$451.99M	$9.68M	N/A	67	News Coverage Positive News Insider Trade
ALVO Alvotech	3.4187 of 5 stars	$5.95 -3.3%	$8.50 +43.0%	-32.3%	$1.80B	$588.90M	N/A	1,460	News Coverage Positive News Analyst Upgrade
VIR Vir Biotechnology	2.5976 of 5 stars	$10.41 -1.0%	$21.57 +107.3%	+103.5%	$1.76B	$68.56M	N/A	367	Trending News Analyst Downgrade
NVAX Novavax	2.0406 of 5 stars	$10.59 -1.9%	$14.00 +32.2%	+21.7%	$1.75B	$1.12B	N/A	749	Options Volume
ZBIO Zenas BioPharma	2.3669 of 5 stars	$26.27 -4.6%	$45.71 +74.0%	+35.2%	$1.72B	$10M	N/A	167	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTA) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prothena (PRTA) Competitors